SHANGHAI – Canbridge Life Sciences Inc. has confirmed the existence of ligand CD95 in Chinese glioblastoma patients after completing the first such biomarker study of its kind on the mainland. The study demonstrated a high degree of CD95 ligand expression consistency between geographically diverse Chinese and Western glioblastoma multiforme patients.